E J Kanfer
Overview
Explore the profile of E J Kanfer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramaswami R, Dalla Pria A, Parker K, McCann S, Kanfer E, Nelson M, et al.
Bone Marrow Transplant
. 2016 Sep;
51(12):1609-1611.
PMID: 27595283
No abstract available.
2.
Perz J, Giles C, Szydlo R, OShea D, Sanz J, Chaidos A, et al.
Bone Marrow Transplant
. 2006 Nov;
39(1):41-7.
PMID: 17115062
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a recognized treatment option for patients with relapsed Hodgkin's lymphoma. We have analysed 67 patients who underwent ASCT after LACE...
3.
El-Helw L, Seckl M, Haynes R, Evans L, Lorigan P, Long J, et al.
Br J Cancer
. 2005 Oct;
93(6):620-1.
PMID: 16222307
We present retrospectively our experience in the use of high-dose chemotherapy and haematopoietic stem cell support (HSCS) for refractory gestational trophoblastic neoplasia (GTN) in the largest series so far reported....
4.
Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours
McNeish I, Kanfer E, Haynes R, Giles C, Harland S, Driver D, et al.
Br J Cancer
. 2004 Mar;
90(6):1169-75.
PMID: 15026797
High-dose regimes containing etoposide, carboplatin and an oxazaphospharine can salvage 30-40% of patients with relapsed or refractory male germ cell tumours (GCTs). The additional benefit of paclitaxel in such high-dose...
5.
Olavarria E, Kanfer E
Curr Opin Hematol
. 2000 Apr;
7(3):191-6.
PMID: 10786658
Peripheral blood progenitor cells (PBPCs) have become the preferred means of stem cell support for high-dose chemotherapy in recent years. The biology of PBPC mobilization is complex and may be...
6.
Gupta D, Bybee A, Cooke F, Giles C, Davis J, McDonald C, et al.
Br J Haematol
. 1999 Feb;
104(1):166-77.
PMID: 10027730
Thirty-six patients with multiple myeloma (23 PR1, nine PR2, four stable disease) were entered into a pilot study evaluating the use of CD34+-selected peripheral blood progenitor cell transplantation (PBPCT) following...
7.
Kanfer E, McGuigan D, Samson D, Abboudi Z, Abrahamson G, Apperley J, et al.
Br J Cancer
. 1998 Oct;
78(7):928-32.
PMID: 9764585
High-dose etoposide (2.0-2.4 g m(-2)) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize peripheral blood progenitor cells (PBPCs), although in some patients this is associated with significant...
8.
Lyttelton M, Newlands E, Giles C, Bower M, Guimaraes A, OReilly S, et al.
Br J Cancer
. 1998 Jul;
77(10):1672-6.
PMID: 9635847
Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death...
9.
Kanfer E, Nicol B
J R Soc Med
. 1997 Jan;
90(1):16-8.
PMID: 9059375
The erythrocyte sedimentation rate (ESR) remains a commonly measured indicator of disease, but is subject to several non-disease influences. The haemoglobin concentration (Hb) and ESR were measured in 1249 consecutive...
10.
Elliott C, Samson D, Armitage S, Lyttelton M, McGuigan D, Hargreaves R, et al.
J Clin Oncol
. 1996 Mar;
14(3):970-3.
PMID: 8622047
Purpose: To evaluate whether the CD34+ yield from a single peripheral-blood stem-cell (PBSC) harvest could be predicted by measurement of the patient's circulating WBC and CD34+ cell concentrations on the...